DCPG
Identifiers
  • 4-[(1S)-1-amino-2-hydroxy-2-oxoethyl]phthalic acid
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
CompTox Dashboard (EPA)
ECHA InfoCard100.161.870 Edit this at Wikidata
Chemical and physical data
FormulaC10H9NO6
Molar mass239.183 g·mol−1
3D model (JSmol)
  • O=C(O)[C@@H](N)c1cc(c(C(=O)O)cc1)C(=O)O
  • InChI=1S/C10H9NO6/c11-7(10(16)17)4-1-2-5(8(12)13)6(3-4)9(14)15/h1-3,7H,11H2,(H,12,13)(H,14,15)(H,16,17)/t7-/m0/s1 ☒N
  • Key:IJVMOGKBEVRBPP-ZETCQYMHSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

DCPG ((S)-3,4-DCPG) is a drug used in scientific research, which acts as a potent and subtype-selective agonist for the metabotropic glutamate receptor mGluR8. It has anticonvulsant effects in animal studies,[1][2] and has also been investigated as a possible treatment for hyperalgesia.[3]

References

  1. ^ Moldrich RX, Chapman AG, De Sarro G, Meldrum BS (August 2003). "Glutamate metabotropic receptors as targets for drug therapy in epilepsy". European Journal of Pharmacology. 476 (1–2): 3–16. doi:10.1016/s0014-2999(03)02149-6. PMID 12969743.
  2. ^ Folbergrová J, Druga R, Haugvicová R, Mares P, Otáhal J (March 2008). "Anticonvulsant and neuroprotective effect of (S)-3,4-dicarboxyphenylglycine against seizures induced in immature rats by homocysteic acid". Neuropharmacology. 54 (4): 665–75. doi:10.1016/j.neuropharm.2007.11.015. PMID 18191956. S2CID 20697899.
  3. ^ Marabese I, de Novellis V, Palazzo E, Scafuro MA, Vita D, Rossi F, Maione S (February 2007). "Effects of (S)-3,4-DCPG, an mGlu8 receptor agonist, on inflammatory and neuropathic pain in mice". Neuropharmacology. 52 (2): 253–62. doi:10.1016/j.neuropharm.2006.04.006. PMID 17113112. S2CID 25646746.
Categories